Skip to content

OPIANT PHARMACEUTICALS, INC.

Delisted

CIK 1385508fmd_0AH7QK19GRDQ9P5CE94MQ1ZN98Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Aug 01, 2005 to Sep 30, 2022, 58 periods

Latest annual · FY2021

Millions
Total revenues
48
Gross profit
41
Operating income
5
Net income
3
Free cash flow
2

Latest quarter · Q3 FY2022

Millions
Total revenues
0
Operating income
(10)
Net income
(10)
Free cash flow
(5)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2018 to FY2021
+50.6%
Revenue, 5 yearsFY2017 to FY2021
+21.0%
Net income, 5 yearsFY2017 to FY2021
n/m

OPIANT PHARMACEUTICALS, INC. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2021FY2020ChangeSource
Revenue$47.8 million$29.6 million+61.3%10-K 2022-03-15 · proof
Operating income$5.2 million-$2.2 million10-K 2022-03-15 · proof
Net income$3 million-$1.9 million10-K 2022-03-15 · proof
Cash from operating activities$1.9 million-$2 million10-K 2022-03-15 · proof
Free cash flow$1.9 million-$2.1 million10-K 2022-03-15 · proof
Total assets$70.4 million$60.6 million+16.2%10-K 2022-03-15 · proof
Total liabilities$23.6 million$25.1 million-6.1%10-K 2022-03-15 · proof
Cash and cash equivalents$37.9 million$48.3 million-21.5%10-K 2022-03-15 · proof
What was OPIANT PHARMACEUTICALS, INC.'s revenue in fiscal 2021?
OPIANT PHARMACEUTICALS, INC. reported revenue of $47.8 million for fiscal 2021 (the year ended Dec 31, 2021), against $29.6 million the year before (+61.3%). Source: the 10-K filed with the SEC on Mar 15, 2022. SEC
What was OPIANT PHARMACEUTICALS, INC.'s operating income in fiscal 2021?
OPIANT PHARMACEUTICALS, INC. reported operating income of $5.2 million for fiscal 2021 (the year ended Dec 31, 2021), against -$2.2 million the year before. Source: the 10-K filed with the SEC on Mar 15, 2022. SEC
What was OPIANT PHARMACEUTICALS, INC.'s net income in fiscal 2021?
OPIANT PHARMACEUTICALS, INC. reported net income of $3 million for fiscal 2021 (the year ended Dec 31, 2021), against -$1.9 million the year before. Source: the 10-K filed with the SEC on Mar 15, 2022. SEC
What was OPIANT PHARMACEUTICALS, INC.'s cash from operating activities in fiscal 2021?
OPIANT PHARMACEUTICALS, INC. reported cash from operating activities of $1.9 million for fiscal 2021 (the year ended Dec 31, 2021), against -$2 million the year before. Source: the 10-K filed with the SEC on Mar 15, 2022. SEC
What was OPIANT PHARMACEUTICALS, INC.'s free cash flow in fiscal 2021?
OPIANT PHARMACEUTICALS, INC. reported free cash flow of $1.9 million for fiscal 2021 (the year ended Dec 31, 2021), against -$2.1 million the year before. Source: the 10-K filed with the SEC on Mar 15, 2022. SEC
What are OPIANT PHARMACEUTICALS, INC.'s total assets?
As of Dec 31, 2021, OPIANT PHARMACEUTICALS, INC. reported total assets of $70.4 million, against $60.6 million a year earlier (+16.2%). Source: the 10-K filed with the SEC on Mar 15, 2022. SEC
What are OPIANT PHARMACEUTICALS, INC.'s total liabilities?
As of Dec 31, 2021, OPIANT PHARMACEUTICALS, INC. reported total liabilities of $23.6 million, against $25.1 million a year earlier (-6.1%). Source: the 10-K filed with the SEC on Mar 15, 2022. SEC
What are OPIANT PHARMACEUTICALS, INC.'s cash and cash equivalents?
As of Dec 31, 2021, OPIANT PHARMACEUTICALS, INC. reported cash and cash equivalents of $37.9 million, against $48.3 million a year earlier (-21.5%). Source: the 10-K filed with the SEC on Mar 15, 2022. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1385508&period_type=annual&limit=5"

Information only, not investment advice.